CLINCIANS’ WEBINAR: Psychedelic-Assisted Therapies Q&A

Join this FREE WEBINAR. Don’t miss out – Get your tickets early!

Psychedelic-Assisted Therapies Q&A for Clinicians

Presented by Dr Lauren Macdonald (UK), Dr Ted Cassidy & Peter Hunt AM

There are only a matter of weeks to go until MDMA & psilocybin-assisted therapies become available in Australia outside of clinical trials. Clinicians are filled with questions, as they wonder how things will progress once July 1st comes.

And so we would like to invite students and graduates of our CPAT program and other clinicians to join us for this important Q&A session. It will be illuminating and clarifying for all.

In this session, we will cover:

1. What’s going to happen from July?

Co-founder of Monarch Mental Health Dr Ted Cassidy & Chair of MMA Peter Hunt AM will answer questions from community members such as:

1. How does the authorised prescriber process work?
   What will the roll out look like at a clinic actively offering PAT?
   What do doctors interested in supporting PAT need to know?
   What options exist for non-psychiatrists wanting to get started working with PAT?

2. What’s it like working as a psychedelic therapist?

Dr Lauren Macdonald from Imperial College London will share her perspective on the experience of working clinically with psychedelics. You’ll learn:

1. How to develop as a skillful, safe and ethical psychedelic-assisted therapist.
2. What are some of the biggest challenges for clinicians entering this space to consider?
3. What advice would you give to clinicians before their first dosing session?

We’ll be accepting written questions before and during the webinar. You’ll find a link to submit questions in your confirmation email.

Date: Tuesday 6 June 2023

Time: 6:25pm for 6:30pm start – 7:45pm (incl Q&A) (AEST)
The presentation WILL BEGIN AT 6:30pm.

Location: Online. A link will be emailed to you with the viewing details

Don’t miss out – Get your tickets early!

More about medicinal psychedelic treatments:

Psychedelic-assisted treatments offer enormous potential in providing a meaningful alternative to current treatments for mental illness. PTSD is a debilitating condition that affects tens of millions of people worldwide, with many more trauma victims diagnosed with comorbid conditions such as depression, anxiety and eating disorders. In recent clinical trials, MDMA has been shown to produce reliable clinical improvements, restoring patient safety and self-agency even for individuals who have suffered with PTSD for many years, and for whom many treatments have failed.

The wave of clinical psychedelic research and regulatory support is rapidly building, with experts forecasting the availability of psychedelic-assisted treatments in the US and EU within the next 2 to 5 years, subject to positive clinical outcomes in large trials that are currently underway.

Disclaimer: Mind Medicine Australia does not encourage or facilitate illegal use of psychedelics or plant medicines. MMA focus is focused on clinical and legal use only supported by the emerging science and legislative processes. Mind Medicine Australia reserves the right to record and publish webinars on various social media platforms. You agree that you will not discuss any names, locations or specific details of illegal use of psychedelics both verbally or via any written forms of communication via Mind Medicine Australia social media platforms (for example Facebook, Instagram or Zoom private and public chat forms during a webinar). Breaches of these guidelines may result in not being able to participate in the event. We thank you for support and cooperation on these matters.